I got a free Priority Pass membership with my credit card. It's not as useful as I'd hoped, but it's a pretty good value.
My Capital One Venture X comes with a free Priority Pass membership that gets me access to over 1,700 airport lounges, but ...
Cure Today1d
FDA Accepts New Drug Application For Taletrectinib in ROS1+ NSCLC
The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...
Monthly Prescribing Reference3d
Avutometinib Plus Defactinib Get Priority Review for Rare Type of Ovarian Cancer
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...
Cure Today1d
FDA Reviews NDA for Dordaviprone in Recurrent H3 K27M-Mutant Diffuse Glioma
Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with ...
Hosted on MSN3d
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug ...
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
Shares of Verastem surged after the company's new cancer treatment got priority review from regulators. The stock was up 46% at $5.37 on Tuesday. Shares are still down 35% since the start of the year.
Targeted Oncology13d
FDA Grants Taletrectinib Priority Review in ROS1+ Advanced NSCLC
The FDA granted priority review to taletrectinib in ROS1-positive advanced NSCLC, with a target decision date of June 2025.
Business Insider3d
HUTCHMED's Combination Therapy For Lung Cancer Granted Priority Review By NMPA
with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (NMPA).
Business Insider6d
Verastem announces FDA acceptance and Priority Review of NDA for Avutometinib
The NDA, which was completed in October 2024, has been granted Priority Review with a Prescription Drug User Fee Act – PDUFA – action date of June 30, 2025. In addition, the FDA has stated ...
Verastem Oncology's New Cancer Treatment Gets FDA Priority Review
Verastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration. The new drug application for the treatment in ...
Morningstar5d
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
Shares of Verastem surged after the company's new cancer treatment got priority review from regulators. The stock was up 46% at $5.37 on Tuesday. Shares are still down 35% since the start of the year.